Liver-directed gene transfer vectors.

The ultimate goal of liver-directed gene therapy for genetic diseases is the stable expression of a therapeutic transgene in a significant proportion of hepatocytes. This article considers the various liver-directed gene transfer procedures studied so far. Performances and limitations of currently available vector systems are discussed with respect to their clinical relevance. Although some improvements have been reported, naked DNA and nonviral gene transfer vectors induce transient expression in only a limited number of cells. Clinical applications of retrovirus-mediated gene transfer are hampered by the need to induce hepatocyte division. First-generation adenovirus vectors are highly efficient; however, they induce an immune response leading to the rapid rejection of transduced cells. Promising new vector systems have emerged, including gutless adenovirus vectors, adeno-associated vectors, and lentivirus vectors. However, these systems are still poorly documented and their relevance to liver-directed gene therapy must be confirmed.

[1]  A. Beaudet,et al.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity , 1998, Nature Genetics.

[2]  Y. Tan,et al.  In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Brough,et al.  Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo , 1997, Journal of virology.

[4]  D. Tyrrell,et al.  Development of replicative and nonreplicative hepatitis B virus vectors , 1997, Gene Therapy.

[5]  F. Alt,et al.  Gene Transfer into Hepatocytes Mediated by Helper Virus-Free HSV/AAV Hybrid Vectors , 1997, Molecular medicine.

[6]  J. Behr,et al.  In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. , 1997, Bioconjugate chemistry.

[7]  D. Peterson,et al.  Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors , 1997, Nature Genetics.

[8]  N. Armstrong,et al.  Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. , 1997, Human gene therapy.

[9]  J. Roy-Chowdhury,et al.  Transient immunosuppression with FK506 permits long‐term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat , 1997, Hepatology.

[10]  F. Cosset,et al.  Highly efficient retrovirus-mediated gene transfer into rat hepatocytes in vivo. , 1997, Human gene therapy.

[11]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[12]  R. DeMatteo,et al.  Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression , 1997, Journal of virology.

[13]  P. Opolon,et al.  Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses , 1997, Journal of virology.

[14]  D. Farson,et al.  Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector , 1997, Gene Therapy.

[15]  M. Kay,et al.  Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. , 1997, Human gene therapy.

[16]  G. Droguett,et al.  Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Droguett,et al.  Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. , 1997, The Journal of clinical investigation.

[18]  S. Cai,et al.  Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. , 1997, Blood.

[19]  R. DeMatteo,et al.  Immunologic barriers to hepatic adenoviral gene therapy for transplantation. , 1997, Transplantation.

[20]  B. Davidson,et al.  Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. , 1996, The Journal of clinical investigation.

[21]  J. Wilson,et al.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.

[22]  M. Horwitz,et al.  Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. , 1996, The Journal of clinical investigation.

[23]  S. Cai,et al.  Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. , 1996, Human gene therapy.

[24]  R. Flavell,et al.  Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues , 1996, Journal of virology.

[25]  J. Wilson,et al.  Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. , 1996, Human gene therapy.

[26]  S. Knechtle,et al.  Naked DNA delivered intraportally expresses efficiently in hepatocytes. , 1996, Gene therapy.

[27]  M Monsigny,et al.  Putative role of chloroquine in gene transfer into a human hepatoma cell line by DNA/lactosylated polylysine complexes. , 1996, Experimental cell research.

[28]  F. Askari,et al.  Complete correction of hyperbilirubinemia in the Gunn rat model of Crigler-Najjar syndrome type I following transient in vivo adenovirus-mediated expression of human bilirubin UDP-glucuronosyltransferase. , 1996, Gene therapy.

[29]  M. Grompe,et al.  Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I , 1996, Nature Genetics.

[30]  D. Bellinger,et al.  Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. , 1996, Gene therapy.

[31]  S. Aliño,et al.  Human α1-Antitrypsin Gene Transfer to In Vivo Mouse Hepatocytes , 1996 .

[32]  E. Furth,et al.  Prolonged Metabolic Correction in Adult Ornithine Transcarbamylase-deficient Mice with Adenoviral Vectors (*) , 1996, The Journal of Biological Chemistry.

[33]  R. M. Hays,et al.  Microtubular Disruption Prolongs the Expression of Human Bilirubin-uridinediphosphoglucuronate-glucuronosyltransferase-1 Gene Transferred into Gunn Rat Livers (*) , 1996, The Journal of Biological Chemistry.

[34]  D. Rader,et al.  A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia , 1995, Nature Medicine.

[35]  James M. Wilson,et al.  Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. , 1995, Journal of immunology.

[36]  D. Blumberg,et al.  Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors , 1995, Hepatology.

[37]  M. Kay,et al.  Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  F. Askari,et al.  Retrovirus-mediated expression of HUG Br1 in Crigler-Najjar syndrome type I human fibroblasts and correction of the genetic defect in Gunn rat hepatocytes. , 1995, Gene therapy.

[39]  J. Behr,et al.  Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: a stage toward artificial viruses. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Armendáriz-Borunda,et al.  Nonenzymatic glycosylation of poly‐l‐lysine: A new tool for targeted gene delivery , 1994, Hepatology.

[41]  L. Leinwand,et al.  The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. , 1994, Gene therapy.

[42]  N. Ferry,et al.  Factors influencing retroviral-mediated gene transfer into hepatocytes in vivo. , 1994, Human gene therapy.

[43]  J. Wilson,et al.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Wilson,et al.  In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. , 1994, The Journal of biological chemistry.

[46]  J. C. Perales,et al.  Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Wu,et al.  Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression. , 1994, The Journal of biological chemistry.

[48]  J. Wilson,et al.  Biochemical and functional analysis of an adenovirus-based ligand complex for gene transfer. , 1994, The Biochemical journal.

[49]  James M. Wilson,et al.  Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia , 1994, Nature Genetics.

[50]  M. Kay,et al.  Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[51]  B. Trapnell,et al.  Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice , 1993, Nature Genetics.

[52]  M. Kay,et al.  In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. , 1993, Science.

[53]  O. Danos,et al.  In situ retrovirus-mediated gene transfer into dog liver. , 1993, Human gene therapy.

[54]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[55]  M. Kay,et al.  Assessment of recombinant adenoviral vectors for hepatic gene therapy. , 1993, Human gene therapy.

[56]  N. Yang,et al.  In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Curiel,et al.  Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. , 1993, The Journal of biological chemistry.

[58]  L. Smith,et al.  Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Monsigny,et al.  Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. , 1993, Nucleic acids research.

[60]  M. Kay,et al.  Hepatic Gene Therapy: Persistent Expression of Human α1-Antitrypsin in Mice after Direct Gene Delivery In Vivo , 1992 .

[61]  F. Ledley,et al.  Correction of methylmalonyl-CoA mutase deficiency inMuto fibroblasts and constitution of gene expression in primary human hepatocytes by retroviral-mediated gene transfer , 1992, Somatic cell and molecular genetics.

[62]  S. Thorgeirsson,et al.  Adenovirus–mediated in vivo gene transfer and expression in normal rat liver , 1992, Nature Genetics.

[63]  J. Rozga,et al.  A model for directed foreign gene delivery to rat liver cells in vivo. , 1992, The Journal of surgical research.

[64]  C. Caskey,et al.  Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice. , 1992, Human gene therapy.

[65]  J. Wilson,et al.  Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. , 1992, The Journal of biological chemistry.

[66]  J. Wilson,et al.  Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. , 1991, Science.

[67]  O. Danos,et al.  Retroviral-mediated gene transfer into hepatocytes in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Pollack,et al.  cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA , 1991, Journal of virology.

[69]  R. Mulligan,et al.  Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[70]  R. Lerner,et al.  Antibody remodeling: a general solution to the design of a metal-coordination site in an antibody binding pocket. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[71]  G. Darlington,et al.  Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[72]  C. Chang,et al.  Encapsidation of truncated human hepatitis B virus genomes through trans-complementation of the core protein and polymerase. , 1990, Virology.

[73]  K. Furtak,et al.  Synthesis of hepadnavirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells , 1990, Journal of virology.

[74]  F. Ledley,et al.  Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[75]  C. Wu,et al.  Receptor-mediated gene delivery and expression in vivo. , 1988, The Journal of biological chemistry.

[76]  R. Mulligan,et al.  Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[77]  R. Mulligan,et al.  Retrovirus-mediated transduction of adult hepatocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[78]  F. Ledley,et al.  Retroviral gene transfer into primary hepatocytes: implications for genetic therapy of liver-specific functions. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Yee,et al.  Gene expression from transcriptionally disabled retroviral vectors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[80]  N. Benvenisty,et al.  Direct introduction of genes into rats and expression of the genes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[81]  T. Dubensky,et al.  Direct transfection of viral and plasmid DNA into the liver or spleen of mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[82]  P. Bosma,et al.  Long-term reduction of serum bilirubin levels in Gunn rats by retroviral gene transfer in vivo. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[83]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.

[84]  J. Miyazaki,et al.  In vivo correction with recombinant adenovirus of 4-hydroxyphenylpyruvic acid dioxygenase deficiencies in strain III mice. , 1997, Human gene therapy.

[85]  C. Wu,et al.  Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. , 1994, Nucleic acids research.

[86]  J. Garcia,et al.  Persistent gene expression after retroviral gene transfer into liver cells in vivo. , 1991, Human gene therapy.

[87]  M. Perricaudet,et al.  Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. , 1990, Human gene therapy.